Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1000 of 2228 entries
View as:

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04011475 Org: User:
Start: 12/29/19 End: 10/31/20 Due: 10/31/21

Observational Non-Interventional Study With Spiriva Respimat in COPD Patients

Phase: N/A Priority: Normal
NCT ID: NCT00699699 Org: User:
Start: 06/30/08 End: - Due: -

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02211989 Org: User:
Start: 02/28/06 End: - Due: -

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Phase: N/A Priority: Normal
NCT ID: NCT02802345 Org: User:
Start: 06/30/16 End: 04/13/18 Due: 04/13/19

Safety Tolerability and Pharmacokinetic of BI 409306

Phase: N/A Priority: Normal
NCT ID: NCT01343706 Org: User:
Start: 04/01/11 End: 08/05/11 Due: 08/05/12

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Phase: N/A Priority: Normal
NCT ID: NCT05421338 Org: User:
Start: 07/04/22 End: 11/17/22 Due: 11/17/23

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01330316 Org: User:
Start: 07/31/11 End: 06/30/14 Due: 06/30/15

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Phase: N/A Priority: Normal
NCT ID: NCT04835714 Org: User:
Start: 04/20/21 End: 01/18/22 Due: 01/18/23

A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

Phase: N/A Priority: Normal
NCT ID: NCT00279747 Org: User:
Start: 09/30/00 End: 01/31/03 Due: 01/31/04

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01629849 Org: User:
Start: 07/31/12 End: 12/31/12 Due: 12/31/13

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02229773 Org: User:
Start: 01/31/00 End: - Due: -

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Phase: N/A Priority: Normal
NCT ID: NCT02262637 Org: User:
Start: 09/30/03 End: - Due: -

Monotherapy Dose Finding With BI 847325 in Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01324830 Org: User:
Start: 04/15/11 End: 10/10/13 Due: 10/10/14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT00809133 Org: User:
Start: 05/31/07 End: 02/28/15 Due: 02/28/16

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT01874483 Org: User:
Start: 06/30/13 End: 12/31/13 Due: 12/31/14

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01111331 Org: User:
Start: 05/31/10 End: - Due: -

Spiriva® Assessment of FEV1 (SAFE)

Phase: N/A Priority: Normal
NCT ID: NCT00277264 Org: User:
Start: 01/31/02 End: 05/31/04 Due: 05/31/05

Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

Phase: N/A Priority: Normal
NCT ID: NCT02173795 Org: User:
Start: 10/31/02 End: - Due: -

Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study

Phase: N/A Priority: Normal
NCT ID: NCT02195505 Org: User:
Start: 09/30/01 End: - Due: -

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Phase: N/A Priority: Normal
NCT ID: NCT01358864 Org: User:
Start: 06/30/11 End: 05/31/14 Due: 05/31/15

Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02261116 Org: User:
Start: 04/30/02 End: - Due: -

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00240422 Org: User:
Start: 02/28/03 End: 07/31/04 Due: 07/31/05

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02262546 Org: User:
Start: 05/31/07 End: - Due: -

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT02240706 Org: User:
Start: 01/22/15 End: 11/18/19 Due: 11/18/20

Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02513446 Org: User:
Start: 09/29/15 End: 11/20/15 Due: 11/20/16